Inhibition of Prolyl Hydroxylase Protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Neurotoxicity

Hypoxia-inducible factor (HIF) plays an important role in cell survival by regulating iron, antioxidant defense, and mitochondrial function. Pharmacological inhibitors of the iron-dependent enzyme class prolyl hydroxylases (PHD), which target α subunits of HIF proteins for degradation, have recently been demonstrated to alleviate neurodegeneration associated with stroke and hypoxic-ischemic injuries. Here we report that inhibition of PHD by 3,4-dihydroxybenzoate (DHB) protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigral dopaminergic cell loss and up-regulates HIF-1α within these neurons. Elevations in mRNA and protein levels of HIF-dependent genes heme oxygenase-1 (Ho-1) and manganese superoxide dismutase (Mnsod) following DHB pretreatment alone are also maintained in the presence of MPTP. MPTP-induced reductions in ferroportin and elevations in nigral and striatal iron levels were reverted to levels comparable with that of untreated controls with DHB pretreatment. Reductions in pyruvate dehydrogenase mRNA and activity resulting from MPTP were also found to be attenuated by DHB. In vitro, the HIF pathway was activated in N27 cells grown at 3% oxygen treated with either PHD inhibitors or an iron chelator. Concordant with our in vivo data, the MPP+-elicited increase in total iron as well as decreases in cell viability were attenuated in the presence of DHB. Taken together, these data suggest that protection against MPTP neurotoxicity may be mediated by alterations in iron homeostasis and defense against oxidative stress and mitochondrial dysfunction brought about by cellular HIF-1α induction. This study provides novel data extending the possible therapeutic utility of HIF induction to a Parkinson disease model of neurodegeneration, which may prove beneficial not only in this disorder itself but also in other diseases associated with metal-induced oxidative stress.

[1]  J. Shay,et al.  Inexpensive low-oxygen incubators , 2006, Nature Protocols.

[2]  T. Yasuhara,et al.  Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease , 2004, The European journal of neuroscience.

[3]  D. Graham,et al.  Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.

[4]  C. Cosi,et al.  Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide , 1998, Brain Research.

[5]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[6]  D. Ferriero,et al.  Regulation of hypoxia-inducible factor 1α and induction of vascular endothelial growth factor in a rat neonatal stroke model , 2003, Neurobiology of Disease.

[7]  J. Connor,et al.  Distribution of divalent metal transporter-1 in the monkey basal ganglia , 2004, Neuroscience.

[8]  Subramanian Rajagopalan,et al.  Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.

[9]  P. Francis,et al.  Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY‐5Y cells , 2008, Journal of neurochemistry.

[10]  A. Flegal,et al.  Stable isotopic tracers of lead mobilized by DMSA chelation in low lead-exposed rats. , 1992, Toxicology and applied pharmacology.

[11]  S. D. Brady,et al.  Haem oxygenase-1 prevents cell death by regulating cellular iron , 1999, Nature Cell Biology.

[12]  Kan Ding,et al.  Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1−/− mice , 2003, Nature Genetics.

[13]  M. Youdim,et al.  Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28 , 2004, Annals of the New York Academy of Sciences.

[14]  David R. Jones,et al.  Role of Iron (II)-2-Oxoglutarate-dependent Dioxygenases in the Generation of Hypoxia-induced Phosphatidic Acid through HIF-1/2 and von Hippel-Lindau-independent Mechanisms* , 2004, Journal of Biological Chemistry.

[15]  C. Marsden,et al.  Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.

[16]  Hong Jiang,et al.  Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP+)-induced apoptosis in MES23.5 cells , 2009, Neurobiology of Aging.

[17]  T. Rouault,et al.  Brain iron metabolism. , 2006, Seminars in pediatric neurology.

[18]  F. Agani,et al.  HIF-1α and VEGF Expression after Transient Global Cerebral Ischemia , 2003 .

[19]  P. W. Hochachka,et al.  Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[21]  R. Koehler,et al.  Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs. , 1995, Stroke.

[22]  D. Ferriero,et al.  A role for hypoxia-inducible factor-1α in desferoxamine neuroprotection , 2005, Neuroscience Letters.

[23]  G. Cohen,et al.  Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Marguerite Wieler,et al.  Midbrain iron content in early Parkinson disease , 2008, Neurology.

[25]  V. Erdmann,et al.  Differentiating the functional role of hypoxia‐inducible factor (HIF)‐1α and HIF‐2α (EPAS‐1) by the use of RNA interference: erythropoietin is a HIF‐2α target gene in Hep3B and Kelly cells , 2004 .

[26]  R. Hammer,et al.  The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. , 1998, Genes & development.

[27]  K. Jin,et al.  From angiogenesis to neuropathology , 2005, Nature.

[28]  J. LaManna,et al.  Hypoxia-inducible Factor Prolyl 4-Hydroxylase Inhibition , 2005, Journal of Biological Chemistry.

[29]  M. Kameda,et al.  Neurorescue effects of VEGF on a rat model of Parkinson's disease , 2005, Brain Research.

[30]  S. Tonegawa,et al.  Reduced stress defense in heme oxygenase 1-deficient cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Charles Duyckaerts,et al.  Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease , 2008, Proceedings of the National Academy of Sciences.

[32]  A. Choi,et al.  Overexpression of heme oxygenase-1 in human pulmonary epithelial cells results in cell growth arrest and increased resistance to hyperoxia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[33]  H. Federoff,et al.  The Good, the Bad, and the Cell Type-Specific Roles of Hypoxia Inducible Factor-1α in Neurons and Astrocytes , 2008, The Journal of Neuroscience.

[34]  J. Hogenesch,et al.  Molecular characterization of the murine Hif-1 alpha locus. , 1997, Gene expression.

[35]  S. Vaulont,et al.  Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. , 2006, Blood.

[36]  Oxana V. Baranova,et al.  Neuron-Specific Inactivation of the Hypoxia Inducible Factor 1α Increases Brain Injury in a Mouse Model of Transient Focal Cerebral Ischemia , 2007, The Journal of Neuroscience.

[37]  A. Harris,et al.  Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. , 1998, Blood.

[38]  B. Brüne,et al.  Nitric oxide reverses desferrioxamine- and hypoxia-evoked HIF-1alpha accumulation--implications for prolyl hydroxylase activity and iron. , 2005, Experimental cell research.

[39]  G. Semenza,et al.  Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. , 1993, Blood.

[40]  G. Semenza,et al.  Age-dependent Defect in Vascular Endothelial Growth Factor Expression Is Associated with Reduced Hypoxia-inducible Factor 1 Activity* , 2000, The Journal of Biological Chemistry.

[41]  Z. Sheng,et al.  Expression of the iron transporter ferroportin in synaptic vesicles and the blood–brain barrier , 2004, Brain Research.

[42]  K. Majamaa,et al.  Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase. , 1986, The Journal of biological chemistry.

[43]  T. Flatmark,et al.  Generation of Reactive Oxygen Species by Tyrosine Hydroxylase: A Possible Contribution to the Degeneration of Dopaminergic Neurons? , 1997, Journal of neurochemistry.

[44]  D. Jiang,et al.  Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice , 2005, Journal of Neural Transmission.

[45]  Jiandie D. Lin,et al.  Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators , 2006, Cell.

[46]  K. Kivirikko,et al.  Characterization of the Human Prolyl 4-Hydroxylases That Modify the Hypoxia-inducible Factor* , 2003, Journal of Biological Chemistry.

[47]  Elsdon Storey,et al.  Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex , 1992, Journal of the Neurological Sciences.

[48]  S. Hirai,et al.  Dopa and dopamine cause cultured neuronal death in the presence of iron , 1991, Journal of the Neurological Sciences.

[49]  Xiaowu Chen,et al.  Intrastriatal gene transfer of vascular endothelial growth factor rescues dopaminergic neurons in a rat Parkinson’s disease model , 2006, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.

[50]  P. Thong,et al.  Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys. , 2003, Free radical biology & medicine.

[51]  Junxia Xie,et al.  Over-expressed human divalent metal transporter 1 is involved in iron accumulation in MES23.5 cells , 2008, Neurochemistry International.

[52]  K. Jin,et al.  Vascular Endothelial Growth Factor Overexpression Delays Neurodegeneration and Prolongs Survival in Amyotrophic Lateral Sclerosis Mice , 2007, The Journal of Neuroscience.

[53]  S. Vaulont,et al.  Deregulation of proteins involved in iron metabolism in hepcidin-deficient mice. , 2005, Blood.

[54]  J. Langston,et al.  Mild parkinsonism in persons exposed to 1‐methyl‐4‐phenyl‐1,2,3,6‐ tetrahydropyridine (MPTP) , 1989, Neurology.

[55]  M. Beal,et al.  Kynurenine Pathway Measurements in Huntington's Disease Striatum: Evidence for Reduced Formation of Kynurenic Acid , 1990, Journal of neurochemistry.

[56]  M. Beal,et al.  Manganese Superoxide Dismutase Overexpression Attenuates MPTP Toxicity , 1998, Neurobiology of Disease.

[57]  A. Harris,et al.  The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages , 2000 .

[58]  R. Ratan,et al.  Translation of Ischemic Preconditioning to the Patient: Prolyl Hydroxylase Inhibition and Hypoxia Inducible Factor-1 as Novel Targets for Stroke Therapy , 2004, Stroke.

[59]  D. Dexter,et al.  Brain iron in the ferrocene-loaded rat: its chelation and influence on dopamine metabolism. , 1995, Biochemical pharmacology.

[60]  M. Holness,et al.  Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. , 2003, Biochemical Society transactions.

[61]  C. Caramelo,et al.  Induction of Hypoxia-inducible Factor 1α Gene Expression by Vascular Endothelial Growth Factor* , 2008, Journal of Biological Chemistry.

[62]  James R. Connor,et al.  Cellular management of iron in the brain , 1995, Journal of the Neurological Sciences.

[63]  Junxia Xie,et al.  Rg1 reduces nigral iron levels of MPTP-treated C57BL6 mice by regulating certain iron transport proteins , 2009, Neurochemistry International.

[64]  K. Jin,et al.  VEGF and ALS: the luckiest growth factor? , 2004, Trends in molecular medicine.

[65]  R. Johnson,et al.  Acute postnatal ablation of Hif-2α results in anemia , 2007, Proceedings of the National Academy of Sciences.

[66]  J. Alam,et al.  Induction of heme oxygenase in toxic renal injury: a protective role in cisplatin nephrotoxicity in the rat. , 1995, Kidney international.

[67]  N. Denko,et al.  HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. , 2006, Cell metabolism.